The treatment of Alcohol Use Disorder (AUD) has traditionally relied on behavioral therapies, support groups, and a limited number of pharmacological interventions such as naltrexone, acamprosate, and disulfiram. However, emerging research suggests that glucagon-like peptide-1 (GLP-1) receptor agonists—commonly used in treating type 2 diabetes and obesity—may offer new promise in treating AUD. Medications such as semaglutide (Ozempic) and tirzepatide (Mounjaro), which affect appetite and reward pathways, are now being investigated as pharmacological adjuncts to help people reduce or stop alcohol consumption. This article briefly summarizes the evidence, benefits, limitations, and potential best candidates for GLP-1 agonist treatment for alcohol use problems, considering both harm reduction (moderate, safer drinking) and abstinence

© Psychology Today